Lisa M Boucher1,2, Ahmed M Bayoumi3,4, Amy E Mark5, Curtis Cooper6, Alana Martin6, Zack Marshall7, Rob Boyd8, Pam Oickle9, Nicola Diliso10, Dave Pineau10, Brad Renaud10, Sean LeBlanc11, Mark Tyndall12, Olivia M Lee2, Claire E Kendall1,2,13. 1. a Bruyere Research Institute , Ottawa , Ontario , Canada. 2. b Department of Epidemiology and Public Health , University of Ottawa , Ottawa , Ontario , Canada. 3. c Division of General Internal Medicine , St. Michael's Hospital , Ontario , Canada. 4. d Department of Medicine and Institute of Health Policy, Management, and Evaluation , University of Toronto , Toronto , Ontario , Canada. 5. e Institute for Clinical Evaluative Sciences , Toronto , Canada. 6. f Clinical Epidemiology Program , Ottawa Hospital Research Institute , Ottawa , Ontario , Canada. 7. g School of Social Work , McGill University , Montreal , Quebec , Canada. 8. h Sandy Hill Community Health Centre , Ottawa , Ontario , Canada. 9. i Ottawa Public Health , Ottawa , Ontario , Canada. 10. j PROUD Community Advisory Committee , Ottawa , Ontario , Canada. 11. k Drug Users Advocacy League , Ottawa , Ontario , Canada. 12. l BC Centre for Disease Control , Vancouver , British Columbia , Canada. 13. m Li Ka Shing Knowledge Institute of St. Michael's Hospital , Ontario , Canada.
Abstract
BACKGROUND: Chronic hepatitis C virus (HCV) infection is common among people who inject drugs (PWID) and is associated with morbidity and premature death. Although HCV can be cured, treatment may be inaccessible. We studied HCV testing, status and treatment among marginalized people who use drugs in Ottawa, Canada, a setting with universal insurance coverage for physician services. METHODS: We analyzed data from the Participatory Research in Ottawa: Understanding Drugs study, a cross-sectional, peer-administered survey of people who use drugs from 2012 to 2013. We linked responses to population-based health administrative databases and used multivariable Poisson regression to identify factors independently associated with self-reported HCV testing, self-reported positive HCV status, and database-determined engagement in HCV treatment. RESULTS: Among 663 participants, 562 (84.8%) reported testing for HCV and 258 (45.9%) reported HCV-positive status. In multivariable analysis, HCV-positive status was associated with female gender (RR 1.27; 95%CI 1.04 to 1.55), advancing age (RR 1.03/year; 95%CI 1.02 to 1.04), receiving disability payments (RR 1.42; 95%CI 1.06 to 1.91), injecting drugs (RR 5.11; 95%CI 2.64 to 9.91), ever injecting with a used needle (RR 1.30; 95%CI 1.12 to 1.52), and ever having taken methadone (RR 1.26; 95%CI 1.05 to 1.52). Of HCV positive participants, 196 (76%) were engaged in primary care but only 23 (8.9%) had received HCV therapy. Conclusions/Importance: Although HCV testing and positive status rates are high among PWID in our study, few have received HCV treatment. Innovative initiatives to increase access to HCV treatment for PWID are urgently needed.
BACKGROUND:Chronic hepatitis C virus (HCV) infection is common among people who inject drugs (PWID) and is associated with morbidity and premature death. Although HCV can be cured, treatment may be inaccessible. We studied HCV testing, status and treatment among marginalized people who use drugs in Ottawa, Canada, a setting with universal insurance coverage for physician services. METHODS: We analyzed data from the Participatory Research in Ottawa: Understanding Drugs study, a cross-sectional, peer-administered survey of people who use drugs from 2012 to 2013. We linked responses to population-based health administrative databases and used multivariable Poisson regression to identify factors independently associated with self-reported HCV testing, self-reported positive HCV status, and database-determined engagement in HCV treatment. RESULTS: Among 663 participants, 562 (84.8%) reported testing for HCV and 258 (45.9%) reported HCV-positive status. In multivariable analysis, HCV-positive status was associated with female gender (RR 1.27; 95%CI 1.04 to 1.55), advancing age (RR 1.03/year; 95%CI 1.02 to 1.04), receiving disability payments (RR 1.42; 95%CI 1.06 to 1.91), injecting drugs (RR 5.11; 95%CI 2.64 to 9.91), ever injecting with a used needle (RR 1.30; 95%CI 1.12 to 1.52), and ever having taken methadone (RR 1.26; 95%CI 1.05 to 1.52). Of HCV positive participants, 196 (76%) were engaged in primary care but only 23 (8.9%) had received HCV therapy. Conclusions/Importance: Although HCV testing and positive status rates are high among PWID in our study, few have received HCV treatment. Innovative initiatives to increase access to HCV treatment for PWID are urgently needed.
Entities:
Keywords:
People who inject drugs; community-based participatory research; health administrative data; hepatitis C testing; hepatitis C treatment
Authors: Judith I Tsui; Claire M Miller; John D Scott; Maria A Corcorran; Julia C Dombrowski; Sara N Glick Journal: Drug Alcohol Depend Date: 2018-12-26 Impact factor: 4.492
Authors: Daniel Winetsky; Daniel Burack; Pantelis Antoniou; Bill Garcia; Peter Gordon; Matthew Scherer Journal: J Infect Dis Date: 2020-09-02 Impact factor: 5.226
Authors: Lisa Townshend-Bulson; Elena Roik; Youssef Barbour; Dana J T Bruden; Chriss E Homan; Hannah G F Espera; Timothy J Stevenson; Annette M Hewitt; Wileina Rhodes; James E Gove; Julia N Plotnik; Mary M Snowball; John McGilvray; Brenna C Simons; Janet M Johnston; Brian J McMahon Journal: PLoS One Date: 2021-12-02 Impact factor: 3.240
Authors: David Whiteley; Elizabeth Speakman; Lawrie Elliott; Katherine Davidson; Emma Hamilton; Helen Jarvis; Michael Quinn; Paul Flowers Journal: J Viral Hepat Date: 2020-12-07 Impact factor: 3.728